Breaking News Instant updates and real-time market news.

PYX

Pyxus

$24.78

1.7 (7.37%)

, TSLA

Tesla

$305.56

-2.2 (-0.71%)

08:45
02/20/19
02/20
08:45
02/20/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Pyxus International (PYX) 81.36% +1.56, Tesla (TSLA) 0.57% +0.32, Ubiquiti (UBNT) 1.69% +0.09, Health Insurance Innovations (HIIQ) 2.37% +0.05, Cronos Group (CRON) 17.49% +0.04, Ambarella (AMBA) 0.47% +0.01, ProShares UltraPro S&P 500 (UPRO) 0.74% +0.01, Lannett (LCI) 3.03% +0.01, Tellurian (TELL) 20.25% +0.01, and AcelRx (ACRX) 5.60% +0.01.

PYX

Pyxus

$24.78

1.7 (7.37%)

TSLA

Tesla

$305.56

-2.2 (-0.71%)

UBNT

Ubiquiti

$138.17

1.88 (1.38%)

HIIQ

Health Insurance Innovations

$43.07

1.83 (4.44%)

CRON

Cronos Group

$21.59

0.31 (1.46%)

AMBA

Ambarella

$39.28

-0.24 (-0.61%)

UPRO

Uproar Inc

$46.80

0.25 (0.54%)

LCI

Lannett

$9.56

-0.265 (-2.70%)

TELL

Tellurian

$9.97

-0.32 (-3.11%)

ACRX

AcelRx

$3.17

0.28 (9.69%)

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 25

    Feb

  • 11

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 19

    Mar

  • 25

    Mar

PYX Pyxus
$24.78

1.7 (7.37%)

TSLA Tesla
$305.56

-2.2 (-0.71%)

02/11/19
ADAM
02/11/19
UPGRADE
Target $450
ADAM
Buy
Canaccord upgrades Tesla to Buy with Model 3, governance concerns eased
As previously reported, Canaccord upgraded Tesla to Buy from Hold with analyst Jed Dorsheimer stating that he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. He believes the last two quarters and recent guidance have removed significant concerns for both production capability and profitability of the Model 3. Also, his prior corporate governance concerns were allayed with the addition of Larry Ellison and Ms. Wilson-Thompson as independent directors, Dorsheimer tells investors. Additionally, he sees Tesla as having "an almost insurmountable lead in autonomous driving," the analyst added in his upgrade note. He raised his price target on Tesla shares to $450 from $330.
02/11/19
02/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Canaccord with analyst Jed Dorsheimer saying he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. 2. Avis Budget (CAR) upgraded to Buy from Sell at Goldman Sachs with analyst David Tamberrino saying trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion. 3. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing the surprise start to Apex Legends' new Battle Royale. 4. Hasbro (HAS) upgraded to Buy from Neutral at Monness Crespi. 5. Lloyds Banking (LYG) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/11/19
ADAM
02/11/19
UPGRADE
ADAM
Buy
Tesla upgraded to Buy from Hold at Canaccord
02/05/19
MSCO
02/05/19
NO CHANGE
Target $283
MSCO
Equal Weight
Morgan Stanley says Tesla managing expectations well, but stock fully valued
Morgan Stanley analyst Adam Jonas said Tesla has "very effectively managed expectations for 1Q19 and the full year," but he also believes the stock remains fully valued. Following the company's recent quarterly report, Jonas cut his 2019 unit volume forecast by 8% to 380,000 vehicles, which drove down his 2019 revenue view to $28B from $30B and led him to lower his price target on Tesla shares to $283 from $291. Jonas, who does not believe investors will assume the company is fully self-sufficient from a funding standpoint without a more sustained period of execution despite its recently strong results, keeps an Equal Weight rating on Tesla shares.
UBNT Ubiquiti
$138.17

1.88 (1.38%)

11/12/18
FBCO
11/12/18
NO CHANGE
Target $86
FBCO
Neutral
Ubiquiti price target raised to $86 from $79 at Credit Suisse
Credit Suisse analyst Sami Badri raised his price target for Ubiquiti to $86 from $79 following quarterly results. The analyst reiterates a Neutral rating on the shares.
11/12/18
BMOC
11/12/18
NO CHANGE
Target $99
BMOC
Market Perform
Ubiquiti price target raised to $99 from $80 at BMO Capital
BMO Capital analyst Tim Long raised his price target on Ubiquiti to $99 after its "strong" Q1 results that were driven by better than expected sales, margins and earnings. The analyst notes that the performance of the company's Enterprise segment was especially impressive, even though its "Service Provider sales continue to lag and the pressures in South America have shown no signs of subsiding". Long keeps his Market Perform on Ubiquiti in spite of its "encouraging" capital return programs because of the "uncertain impact of China tariffs and the challenged Service Provider end market."
02/11/19
BMOC
02/11/19
NO CHANGE
Target $120
BMOC
Market Perform
Ubiquiti price target raised to $120 from $99 at BMO Capital
BMO Capital analyst Tim Long raised his price target on Ubiquiti to $120 after its Q2 earnings, sales, and margins beat across the board. The analyst states that the Enterprise segment drove much of the revenue outperformance, and the rate of decline in Service Provider business was less than expected. Long keeps his Market Perform rating on the shares however, noting the spike in inventories which may reflect concerns about increased tariffs as well as the company's "lack of visibility into sales drivers".
02/11/19
FBCO
02/11/19
NO CHANGE
Target $103
FBCO
Neutral
Ubiquiti price target raised to $103 from $86 at Credit Suisse
Credit Suisse analyst Sami Badri raised his price target for Ubiquiti to $103 from $86 following quarterly results. The analyst reiterates a Neutral rating on the shares.
HIIQ Health Insurance Innovations
$43.07

1.83 (4.44%)

12/21/18
CANT
12/21/18
NO CHANGE
Target $65
CANT
Overweight
Health Insurance shares 'very attractive' here, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper reiterates an Overweight rating on Health Insurance Innovations with a $65 price target following yesterday's investor day. The company indicated that its captive distribution channel, Agile, has seen strong growth in longer-term policies, Halper tells investors in a research note. However, Health Insurance incurred higher acquisition costs and indicated that 2018 results would be at the lower end of its guidance range, adds the analyst. Importantly, the company indicated that it was comfortable with 2019 consensus estimates, says Halper. He believes the shares are "very attractive" at current levels.
12/21/18
RILY
12/21/18
NO CHANGE
Target $55
RILY
Buy
Health Insurance price target lowered to $55 from $60 at B. Riley FBR
B. Riley FBR analyst Randy Binner lowered his price target for Health Insurance Innovations to $55 following yesterday's investor day but reiterates a Buy rating on the shares. The analyst sees a favorable risk/reward at current share levels.
12/21/18
ADAM
12/21/18
NO CHANGE
Target $62
ADAM
Buy
Health Insurance Innovations should be bought aggressively, says Canaccord
Canaccord analyst Richard Close said he would be an aggressive buyer of Health Insurance Innovations shares following its significant pullback. The analyst cited the company's recently updated guidance and his management meeting, which reassured him about the company's focus on compliance and the potential for accelerating growth given industry tailwinds. Close reiterated his Buy rating and $62 price target on Health Insurance Innovations shares.
12/14/18
CHLM
12/14/18
NO CHANGE
Target $65
CHLM
Buy
Health Insurance Innovations settlement removes overhang, says Craig-Hallum
Craig-Hallum analyst George Sutton reiterated a Buy rating and $65 price target on Health Insurance Innovations following yesterday's announcement of the 43-state settlement in its market conduct examination. In a research note to investors, Sutton says the settlement removes the overhang and is likely the start of a series of catalysts that should push the stock higher given that the company can now add new carriers as well as distributors as soon as today
CRON Cronos Group
$21.59

0.31 (1.46%)

02/05/19
MITR
02/05/19
DOWNGRADE
MITR
Hold
Cronos Group downgraded to Hold from Buy at GMP Securities
02/05/19
MITR
02/05/19
DOWNGRADE
Target $24
MITR
Hold
Cronos Group downgraded to Hold on valuation at GMP Securities
As previously reported, GMP Securities analyst Martin Landry downgraded Cronos Group to Hold from Buy with a C$24 price target, citing valuation. In a research note to investors, Landry notes that shares yesterday reached an all-time high of $32.95, surging about 110% year-to-date on no material news. He says his downgrade is not based on any operational issues, as he is a believer in Cronos' "bright" outlook and has no concerns on the company's expansion plans or the execution abilities of its management team, but says shares "need a breather" given the significant appreciation in recent weeks.
02/05/19
02/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Rent-A-Center (RCII) downgraded to Neutral from Buy at Janney Montgomery Scott with analyst John Rowan citing the stock's 50% rise from its intra-day low of $11.98 on December 18, 2018. 2. Equifax (EFX) downgraded to Hold from Buy at Deutsche Bank with analyst Ashish Sabadra saying the shares have rallied significantly off the bottom and outperformed the market year-to-date due to expectations for improving mortgage originations and overall consumer lending. 3. Kraft Heinz (KHC) downgraded to Hold from Buy at Deutsche Bank with analyst Rob Dickerson saying his analysis shows store brands continue to increase distribution points and take share in the majority of Kraft Heinz's largest categories. 4. CenturyLink (CTL) downgraded to Sell from Neutral at Citi with analyst Michael Rollins saying he expects headwinds on revenue and cash flow, a possible dividend cut, and the likelihood for capex upgrades to lead to further multiple contraction. 5. Cronos Group (CRON) downgraded to Hold from Buy at GMP Securities with analyst Martin Landry citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/14/19
COWN
02/14/19
NO CHANGE
COWN
SAFE Act should pass House, Senate path less clear, says Cowen
After the House Financial Services financial institutions subcommittee held a hearing on legislation that would permit banks to provide service to cannabis companies that are in compliance with state law, Cowen analyst Jaret Seiberg said he believes the hearing went well enough for the SAFE Act to pass the committee and the full House later this year. However, the path forward in the Senate is "less clear," said Seiberg. The analyst, whose base call remains that the House passes the SAFE Act and other cannabis laws and that the Senate then pushes through a package before the end of the 116th Congress, expects "positive news by the end of 2020 for cannabis companies," he tells investors. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
AMBA Ambarella
$39.28

-0.24 (-0.61%)

08/31/18
MSCO
08/31/18
NO CHANGE
Target $50
MSCO
Overweight
Morgan Stanley bullishness on Ambarella computer vision opportunity still intact
Morgan Stanley analyst Joseph Moore said a large miss in Ambarella's consumer business, an auto program delay and trade tensions in surveillance will all likely test investor patience, but he remains bullish as his enthusiasm for the new computer vision opportunity has not waned. He thinks the company is hitting its milestones and still expects the company to be able to talk more specifically about autonomous driving customers later this year, Moore tells investors. While his view of the upside has not changed, the downside protection in the event that the company is less successful transitioning to computer vision has declined, added Moore, who keeps an Overweight rating on Ambarella shares but lowered his price target to $50 from $58.
01/14/19
NEED
01/14/19
NO CHANGE
NEED
Hold
Needham more positive on Ambarella processors after CES
Needham analyst N. Quinn Bolton kept his Hold rating on Ambarella after its CES presentations, saying that while the meetings have highlighted a "cautious demand environment" in the industry, he has turned more "positive on the maturity of the company's CVflow". The analyst notes that the combined third party software running on Ambarella 's CV22 processors "offered similar detection and classification performance to competing systems at very low power levels", adding that he was also "impressed with the company's stereo camera based demonstrations for both near-field and far-field object detection and depth perception."
10/29/18
NORL
10/29/18
INITIATION
Target $38
NORL
Outperform
Ambarella initiated with an Outperform at Northland
Northland analyst Gus Richard initiated Ambarella with a Buy and $38 price target saying it is well positioned for growth of Computer Vision. Richard sees multiple catalysts over the next 12 months including the ramp of Computer Vision Products in 1H 2019, adoption in Security Camera market, automotive design wins, and reduced Consumer revenue headwinds.
11/30/18
ROTH
11/30/18
NO CHANGE
Target $40
ROTH
Neutral
Ambarella price target raised to $40 from $35 at Roth Capital
Following Ambarella's Q3 results, Roth Capital analyst Suji Desilva said he believes the name represents a differentiated investment opportunity in low power video and computer vision processor. While revenue from newer CV products remains an intermediate-term opportunity, Desilva says he is encouraged by initial design wins in both surveillance and automotive. While he raises his price target to $40, he remains Neutral and will look for additional computer vision traction prior to getting more constructive in the name.
UPRO Uproar Inc
$46.80

0.25 (0.54%)

LCI Lannett
$9.56

-0.265 (-2.70%)

08/20/18
BMOC
08/20/18
NO CHANGE
BMOC
Market Perform
Lannett price target lowered to $8 from $19 at BMO Capital
BMO Capital analyst Gary Nachman said JSP's decision to not renew its agreement with Lannett (LCI) and go with Amneal Pharmaceuticals (AMRX) is an "unfortunate development" that impacts three products, including Levothyroxine, which accounts for about 35-40% of Lannett revenue and is "very profitable." He lowered his estimates "significantly" due to this "major setback" and cut his price target on Lannett shares to $8 from $19 while maintaining a Market Perform rating on the shares.
08/20/18
08/20/18
DOWNGRADE

Market Perform
Lannett downgraded to Market Perform as JSP walks away from renewal at Raymond James
As previously reported, Raymond James analyst Elliot Wilbur downgraded Lannett to Market Perform from Outperform after Jerome Stevens terminated its strategic distribution agreement with the company, a deal that provided Lannett with several key products but mainly levothyroxine, which is expected to account for 35% of FY18 sales and 44% of gross profit. From a monetary perspective, the analyst believes it makes "zero sense" why JSP would walk away from the deal, inflicting significant damage on its own holdings of Lannett shares. This suggests either JSP has no confidence in the recovery value of its holdings from current levels or has sold down or hedged a substantial portion of its holdings despite prior representations from Lannett management to the contrary, Wilbur contends.
08/20/18
RAJA
08/20/18
DOWNGRADE
RAJA
Market Perform
Lannett downgraded to Market Perform from Outperform at Raymond James
08/20/18
08/20/18
DOWNGRADE
Target $7

Hold
Lannett downgraded to Hold on end of JSP relationship at Craig-Hallum
As previously reported, Craig-Hallum analyst Matt Hewitt downgraded Lannett to Hold from Buy, stating that the ending of the company's "fruitful long-time partnership" with Jerome Stephens Pharmaceuticals is a "significant disappointment" that creates a noticeable cash flow void and creates a risk that the company's debt gets refinanced at higher interest rates. Separate from the JSP announcement, Lannett also preannounced Q4 results that were below consensus, noted Hewitt, who lowered his price target on the stock to $7 from $32. Lannett shares, which were also downgraded earlier to Neutral from Buy at Roth Capital, are down $7.92, or 59%, to $5.58 in afternoon trading.
TELL Tellurian
$9.97

-0.32 (-3.11%)

11/13/18
WOLF
11/13/18
INITIATION
Target $9
WOLF
Peer Perform
Tellurian initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Tellurian with a Peer Perform and $9 price target.
02/08/19
SCOT
02/08/19
INITIATION
Target $12
SCOT
Sector Perform
Tellurian initiated with a Sector Perform at Scotiabank
Scotiabank analyst Alonso Guerra-Garcia initiated Tellurian with a Sector Perform and $12 price target.
11/07/18
BARD
11/07/18
NO CHANGE
BARD
Tellurian named a Fresh Pick at Baird
02/13/19
RAJA
02/13/19
INITIATION
Target $12
RAJA
Outperform
Tellurian initiated with an Outperform at Raymond James
Raymond James analyst Justin Jenkins started coverage of Tellurian with an Outperform rating and $12 price target. As the shifting global energy environment unfolds, low-cost U.S. natural gas stands out as a disruptive theme with unique investment characteristics, the analyst contends, adding that his macro outlook further supports the U.S. LNG export growth theme. Jenkins thinks Tellurian is well-positioned to capitalize on the opportunity set for growth. While some investors view Tellurian as a "binary" story, he thinks that view is overly simplistic, and sees several scenarios for value creation.
ACRX AcelRx
$3.17

0.28 (9.69%)

11/02/18
LTCO
11/02/18
NO CHANGE
Target $10
LTCO
Buy
AcelRx has 'very large market opportunity' for Dsuvia, says Ladenburg
After the FDA approved AcelRx's Dsuvia for the management of acute pain in certified medically supervised healthcare settings, Ladenburg analyst Michael Higgins said data shows there are more than 100M patients with pain in medical institutions annually and about 40M with moderate-to-severe acute pain that receive opioids in the Emergency Department, giving the drug a "very large market opportunity." Adding that forecasting the rate of adoption of a novel drug to hospital formularies is difficult, Higgins left his prior revenue estimates unchanged following the approval news. He reiterates a Buy rating and $10 price target on AcelRx shares.
11/05/18
CANT
11/05/18
NO CHANGE
CANT
AcelRx price target raised to $9 from $8 at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating on AcelRx and raised his price target to $9 from $8 after the approval of Dsuvia and the company's Q3 earnings results. Folkes believes the approval of Dsuvia remained discounted in the stock's price, given the opioid crisis, and now that an overhang has been removed, investors can look forward to the commercial potential of Dsuvia. Additionally, the analyst believes AcelRx's second product, Zalviso, has the potential to gain approval in the U.S. over the next 12 months.
02/15/19
FBCO
02/15/19
INITIATION
Target $7
FBCO
Outperform
AcelRx initiated with an Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan started AcelRx with an Outperform rating and $7 price target, stating that he sees the company as well-positioned to capture market share with its Dsuvia treatment for pain. He also notes the potential for a Zalviso NDA submission in 2019.
02/15/19
02/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cubic (CUB) initiated with a Buy at Citi. 2. Del Frisco's (DFRG) initiated with a Neutral at JPMorgan. 3. Lindblad Expeditions (LIND) initiated with a Buy at Stifel. 4. CareDx (CDNA) initiated with a Buy at Jefferies. 5. AcelRx (ACRX) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary  »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$38.33

-0.36 (-0.93%)

18:29
09/17/19
09/17
18:29
09/17/19
18:29
Hot Stocks
FB Financial acquires FNB Financial »

FB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

GM

General Motors

$38.28

1.07 (2.88%)

18:28
09/17/19
09/17
18:28
09/17/19
18:28
Periodicals
GM stops paying health insurance costs for union workers on strike, Reuters says »

General Motors has moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$52.85

0.08 (0.15%)

18:25
09/17/19
09/17
18:25
09/17/19
18:25
Periodicals
Total CEO says Saudi oil facility strikes will have consequences, Reuters says »

Total CEO Patrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SMMF

Summit Financial Group

$25.96

-0.29 (-1.10%)

18:02
09/17/19
09/17
18:02
09/17/19
18:02
Hot Stocks
Summit Financial and Cornerstone Financial sign merger agreement »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$30.93

-0.89 (-2.80%)

18:01
09/17/19
09/17
18:01
09/17/19
18:01
Earnings
Steel Dynamics sees Q3 EPS 66c-70c, consensus 71c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

18:00
09/17/19
09/17
18:00
09/17/19
18:00
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says FY21 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:59
09/17/19
09/17
17:59
09/17/19
17:59
Hot Stocks
FedEx says new FY20 EPS forecast assumes no further weakening in economic growth »

Says FY20 ground…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

BTI

British American Tobacco

$36.84

0.825 (2.29%)

, PM

Philip Morris

$71.98

-0.54 (-0.74%)

17:57
09/17/19
09/17
17:57
09/17/19
17:57
General News
NY State implements first-in-nation ban on flavored e-cigarettes »

Governor Andrew M. Cuomo…

BTI

British American Tobacco

$36.84

0.825 (2.29%)

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MRK

Merck

$82.53

0.52 (0.63%)

17:57
09/17/19
09/17
17:57
09/17/19
17:57
Hot Stocks
Merck says FDA approves Keytruda-Lenvima combo treatment »

Merck and Eisai announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

ENB

Enbridge

$35.27

0.1 (0.28%)

17:56
09/17/19
09/17
17:56
09/17/19
17:56
Hot Stocks
Enbridge says Minnesota Supreme Court rejects L3RP FEIS appeals »

Enbridge said it supports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:47
09/17/19
09/17
17:47
09/17/19
17:47
Hot Stocks
FedEx EVP Carere says building 'powerful relationships' with many retailers »

Says forged new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.